Gadoquatrane in Contrast-enhanced Head-and-neck and Liver Magnetic Resonance Imaging

The study suggests that gadoquatrane, which demonstrated signal-enhancement kinetics similar to those of gadobutrol and gadoterate meglumine, might be utilized effectively at a dose below 0.05 mmol Gd/kg body weight, independent of the anatomic structure investigated and the pulse sequence employed. Overall, the study supports and complements the results of the clinical dose-response study of gadoquatrane.